2 unknown, 1 completed. 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
Follow Henrik Lindman: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer SPC-flakes, Salovum, Placebo - Early-stage Breast Cancer, Diarrhea | Phase 3 | Unknown | Henrik Lindman | 100 | 2023-06-07 | 2023-11-30 |
| A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer ABY-PET - HER2-positive Breast Cancer | Not applicable | Unknown | Henrik Lindman | 160 | 2018-08-22 | 2021-09-29 |
| Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer 5-FU, epirubicin and cyclophosphamide - Breast Cancer | Phase 3 | Completed | Henrik Lindman | 1535 | 2001-02-01 | 2019-03-28 |
Breast Neoplasms (2) · Diarrhea (1) · Drug-Related Side Effects and Adverse Reactions (1)
Cyclophosphamide (1) · Epirubicin (1) · Fluorouracil (1)
Sweden (2)